Article
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
Proceedings of the National Academy of Sciences of the United States of America - 26 Dec 2007
Bean James, Brennan Cameron, Shih Jin-Yuan, Riely Gregory, Viale Agnes, Wang Lu, Chitale Dhananjay, Motoi Noriko, Szoke Janos, Broderick Stephen, Balak Marissa, Chang Wen-Cheng, Yu Chong-Jen, Gazdar Adi, Pass Harvey, Rusch Valerie, Gerald William, Huang Shiu-Feng, Yang Pan-Chyr, Miller Vincent, Ladanyi Marc, Yang Chih-Hsin, Pao William
Abstract excerpt
In human lung adenocarcinomas harboring EGFR mutations, a second-site point mutation that substitutes methionine for threonine at position 790 (T790M) is associated with approximately half of cases of acquired resistance to the EGFR kinase inhibitors, gefitinib and erlotinib. To identify other potential mechanisms that contribute to disease progression, we used array-based comparative genomic hybridization (aCGH)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.